Evidence map›Paper›PMID 31156622›Full record

ArticleFrontiers in immunology2019

Unusual Cysteine Content in V1 Region of gp120 From an Elite Suppressor That Produces Broadly Neutralizing Antibodies.

Jennie M Hutchinson, Kathryn A Mesa, David L Alexander, Bin Yu, Sara M O'Rourke, Kay L Limoli, Terri Wrin, Steven G Deeks, Phillip W Berman

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Jennie M HutchinsonDepartment of Biomolecular Engineering, University of California, Santa Cruz, Santa Cruz, CA, United States.
Kathryn A MesaDepartment of Biomolecular Engineering, University of California, Santa Cruz, Santa Cruz, CA, United States.
David L AlexanderDepartment of Biomolecular Engineering, University of California, Santa Cruz, Santa Cruz, CA, United States.
Bin YuDepartment of Biomolecular Engineering, University of California, Santa Cruz, Santa Cruz, CA, United States.
Sara M O'RourkeDepartment of Biomolecular Engineering, University of California, Santa Cruz, Santa Cruz, CA, United States.
Kay L LimoliMonogram Biosciences, South San Francisco, CA, United States.
Terri WrinMonogram Biosciences, South San Francisco, CA, United States.
Steven G DeeksDepartment of Medicine, University of California, San Francisco, San Francisco, CA, United States.
Phillip W BermanDepartment of Biomolecular Engineering, University of California, Santa Cruz, Santa Cruz, CA, United States.
University of California, Santa Cruz · USUniversity of California, San Francisco · US

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 1988 to 2026
$93.6M
Enhanced Anti-HIV-1 Antibody Responses in African American Women Seropositive forR01DA036335 · NIDA · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI BERMAN, PHILLIP WAYNE · 2013 to 2017
$3.0M
NIAID NIH HHS P30 AI027763NIDA NIH HHS R01 DA036335
6 · The paper itself

Abstract

Although it is now possible to produce recombinant HIV envelope glycoproteins (Envs) with epitopes recognized by the 5-6 major classes of broadly neutralizing antibodies (bNAbs), these have failed to consistently stimulate the formation of bNAbs in immunized animals or humans. In an effort to identify new immunogens better able to elicit bNAbs, we are studying Envs derived from rare individuals who possess bNAbs and are able to control their infection without the need for anti-retroviral drugs (elite supressors or ES), hypothesizing that in at least some people the antibodies may mediate durable virus control. Because virus evolution in people with the ES only phenotype was reported to be limited, we reasoned the Env proteins recovered from these individuals may more closely resemble the Envs that gave rise to bNAbs compared to the highly diverse viruses isolated from normal progressors. Using a phenotypic assay, we screened 25 controllers and identified two for more detailed investigation. In this study, we examined 20 clade B proviral sequences isolated from an African American woman, who had the rare bNAb/ES phenotype. Phylogenetic analysis of proviral envelope sequences demonstrated low genetic diversity. Envelope proteins were unusual in that most possessed two extra cysteines within an elongated V1 region. In this report, we examine the impact of the extra cysteines on the binding to bNAbs, virus infectivity, and sensitivity to neutralization. These data suggest structural motifs in V1 can affect infectivity, and that rare viruses may be prevented from developing escape.

Indexed as

CysteineAdolescentAdultAgedAmino Acid SequenceBroadly Neutralizing AntibodiesCohort StudiesEpitopesFemaleHIV-1HIV AntibodiesHIV Envelope Protein gp120HIV InfectionsHumansMaleMiddle AgedBroadly Neutralizing AntibodiesCysteineEpitopesHIV AntibodiesHIV Envelope Protein gp120HIV envelope protein gp120 (135-148)Peptide FragmentscontrollerdisulfideEnvgp120HIVprovirussupressorvaccine

Identifiers

PMID31156622
PMCPMC6530427
OpenAlexW2944849028

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.